Clinical Trials
27 trialsNCT01334073 2026-05-14
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT05017012 2026-03-27
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT05904730 2024-12-30
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Lynkcell Europe
Phase 1 Completed
NCT04873895 2024-04-26
TACE-Ax-HCQ
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT05070221 2021-10-07
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT02782403 2020-11-19
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03289533 2020-09-04
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
Phase 1 Completed
NCT00859118 2019-11-19
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
University of Wisconsin, Madison
Phase 1 Completed
NCT01540526 2019-11-19
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
University of Wisconsin, Madison
Phase 1 Completed
NCT03275558 2018-07-19
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
Phase 1 Withdrawn
NCT02164838 2018-01-29
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT01529138 2015-04-13
Study of Axitinib and Temsirolimus in Solid Tumors
Emory University
Phase 1 Completed
NCT00842244 2013-11-27
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00447005 2012-05-23
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00726752 2012-05-23
A Study In Patients With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT00454649 2012-04-04
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
Phase 1 Completed
NCT01469052 2012-03-26
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00949624 2012-01-19
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Arog Pharmaceuticals, Inc.
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn